Corbus Pharmaceuticals Holdings (CRBP) Non Operating Investment Income (2022 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Non Operating Investment Income of -$58000.0 for Q1 2025, up 82.26% year-over-year from -$31822.6 in Q1 2024, and up 82.26% quarter-over-quarter from -$326949.0 in Q1 2024.
Corbus Pharmaceuticals Holdings (CRBP) Non Operating Investment Income (2022 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Non Operating Investment Income history runs 4 years deep, the most recent figure standing at -$58000.0 for Q1 2025.
- In Q1 2025, Non Operating Investment Income rose 82.26% year-over-year to -$58000.0; the TTM figure through Mar 2025 stood at -$362717.0 (down 39.49% YoY), while the FY2023 annual figure was $124536.0, up 295.67% from the prior year.
- Non Operating Investment Income for Q1 2025 stood at -$58000.0, up from -$326949.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $80782.0 in Q4 2022, with the low at -$326949.0 in Q1 2024.
- The 4-year median for Non Operating Investment Income is $11116.0 (2023), against an average of -$32406.0.
- The sharpest annual moves came in 2023 and 2024: Non Operating Investment Income jumped 153.73% in 2023, then slumped 667.39% in 2024.
- Corbus Pharmaceuticals Holdings' Non Operating Investment Income stood at $80782.0 in 2022, then plunged by 91.98% to $6479.0 in 2023, then sank by 5146.29% to -$326949.0 in 2024, then soared by 82.26% to -$58000.0 in 2025.
- Business Quant data shows CRBP's Non Operating Investment Income at -$58000.0 in Q1 2025, -$326949.0 in Q1 2024, and $6479.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -16,000.00 |
| Jun 30, 2025 | -16,000.00 |
| Mar 31, 2025 | -58,000.00 |
| Mar 31, 2025 | -58,000.00 |
| Mar 31, 2024 | -326,949.00 |
| Mar 31, 2024 | -326,949.00 |
| Dec 31, 2023 | 6,479.00 |
| Dec 31, 2023 | 6,479.00 |
| Sep 30, 2023 | 15,753.00 |
| Sep 30, 2023 | 15,753.00 |
| Jun 30, 2023 | 44,681.00 |
| Jun 30, 2023 | 44,681.00 |
| Mar 31, 2023 | 57,623.00 |
| Mar 31, 2023 | 57,623.00 |
| Dec 31, 2022 | 80,782.00 |
| Dec 31, 2022 | 80,782.00 |
| Sep 30, 2022 | -87,554.00 |
| Sep 30, 2022 | -87,554.00 |
| Jun 30, 2022 | 50,373.00 |
| Jun 30, 2022 | 50,373.00 |